Home > Publications database > Noradrenergic enhancement improves motor network connectivity in stroke patients > print

001     12585
005     20210129210556.0
024 7 _ |2 pmid
|a pmid:21387380
024 7 _ |2 DOI
|a 10.1002/ana.22237
024 7 _ |2 WOS
|a WOS:000288284900020
037 _ _ |a PreJuSER-12585
041 _ _ |a eng
082 _ _ |a 610
084 _ _ |2 WoS
|a Clinical Neurology
084 _ _ |2 WoS
|a Neurosciences
100 1 _ |0 P:(DE-Juel1)VDB75806
|a Wang, L.E.
|b 0
|u FZJ
245 _ _ |a Noradrenergic enhancement improves motor network connectivity in stroke patients
260 _ _ |a Hoboken, NJ
|b Wiley-Blackwell
|c 2011
300 _ _ |a 375 - 388
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 0
|2 EndNote
|a Journal Article
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |2 DRIVER
|a article
440 _ 0 |0 451
|a Annals of Neurology
|v 69
|x 0364-5134
|y 2
500 _ _ |a This research was supported by a grant from the Human Brain Project (R01-MH074457-01A1 to S.B.E.) and the Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Systems Biology (Human Brain Model to S.B.E.).
520 _ _ |a Both animal and human data suggest that noradrenergic stimulation may enhance motor performance after brain damage. We conducted a placebo-controlled, double-blind and crossover design study to investigate the effects of noradrenergic stimulation on the cortical motor system in hemiparetic stroke patients.Stroke patients (n = 11) in the subacute or chronic stage with mild-to-moderate hand paresis received a single oral dose of 6 mg reboxetine (RBX), a selective noradrenaline reuptake inhibitor. We used functional magnetic resonance imaging and dynamic causal modeling to assess changes in neural activity and interregional effective connectivity while patients moved their paretic hand.RBX stimulation significantly increased maximum grip power and index finger-tapping frequency of the paretic hand. Enhanced motor performance was associated with a reduction of cortical "hyperactivity" toward physiological levels as observed in healthy control subjects, especially in the ipsilesional ventral premotor cortex (vPMC) and supplementary motor area (SMA), but also in the temporoparietal junction and prefrontal cortex. Connectivity analyses revealed that in stroke patients neural coupling with SMA or vPMC was significantly reduced compared with healthy controls. This "hypoconnectivity" was partially normalized when patients received RBX, especially for the coupling of ipsilesional SMA with primary motor cortex.The data suggest that noradrenergic stimulation by RBX may help to modulate the pathologically altered motor network architecture in stroke patients, resulting in increased coupling of ipsilesional motor areas and thereby improved motor function.
536 _ _ |0 G:(DE-Juel1)FUEK409
|2 G:(DE-HGF)
|x 0
|c FUEK409
|a Funktion und Dysfunktion des Nervensystems (FUEK409)
536 _ _ |0 G:(DE-HGF)POF2-89572
|a 89572 - (Dys-)function and Plasticity (POF2-89572)
|c POF2-89572
|f POF II T
|x 1
588 _ _ |a Dataset connected to Web of Science, Pubmed
650 _ 2 |2 MeSH
|a Adrenergic Uptake Inhibitors: therapeutic use
650 _ 2 |2 MeSH
|a Adult
650 _ 2 |2 MeSH
|a Aged
650 _ 2 |2 MeSH
|a Cross-Over Studies
650 _ 2 |2 MeSH
|a Double-Blind Method
650 _ 2 |2 MeSH
|a Hand Strength: physiology
650 _ 2 |2 MeSH
|a Humans
650 _ 2 |2 MeSH
|a Magnetic Resonance Imaging
650 _ 2 |2 MeSH
|a Male
650 _ 2 |2 MeSH
|a Middle Aged
650 _ 2 |2 MeSH
|a Morpholines: therapeutic use
650 _ 2 |2 MeSH
|a Motor Cortex: drug effects
650 _ 2 |2 MeSH
|a Motor Cortex: physiopathology
650 _ 2 |2 MeSH
|a Paresis: drug therapy
650 _ 2 |2 MeSH
|a Paresis: etiology
650 _ 2 |2 MeSH
|a Paresis: physiopathology
650 _ 2 |2 MeSH
|a Psychomotor Performance: drug effects
650 _ 2 |2 MeSH
|a Recovery of Function: drug effects
650 _ 2 |2 MeSH
|a Stroke: complications
650 _ 2 |2 MeSH
|a Stroke: drug therapy
650 _ 2 |2 MeSH
|a Stroke: physiopathology
650 _ 7 |0 0
|2 NLM Chemicals
|a Adrenergic Uptake Inhibitors
650 _ 7 |0 0
|2 NLM Chemicals
|a Morpholines
650 _ 7 |0 98769-81-4
|2 NLM Chemicals
|a reboxetine
650 _ 7 |2 WoSType
|a J
700 1 _ |0 P:(DE-Juel1)131720
|a Fink, G. R.
|b 1
|u FZJ
700 1 _ |0 P:(DE-HGF)0
|a Diekhoff, S.
|b 2
700 1 _ |0 P:(DE-HGF)0
|a Rehmke, A.K.
|b 3
700 1 _ |0 P:(DE-Juel1)131678
|a Eickhoff, S. B.
|b 4
|u FZJ
700 1 _ |0 P:(DE-HGF)0
|a Grefkes, C.
|b 5
773 _ _ |0 PERI:(DE-600)2037912-2
|a 10.1002/ana.22237
|g Vol. 69, p. 375 - 388
|p 375 - 388
|q 69<375 - 388
|t Annals of neurology
|v 69
|x 0364-5134
|y 2011
856 7 _ |u http://dx.doi.org/10.1002/ana.22237
909 C O |o oai:juser.fz-juelich.de:12585
|p VDB
913 2 _ |0 G:(DE-HGF)POF3-572
|1 G:(DE-HGF)POF3-570
|2 G:(DE-HGF)POF3-500
|a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|v (Dys-)function and Plasticity
|x 0
913 1 _ |0 G:(DE-HGF)POF2-89572
|a DE-HGF
|v (Dys-)function and Plasticity
|x 1
|4 G:(DE-HGF)POF
|1 G:(DE-HGF)POF3-890
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-800
|b Programmungebundene Forschung
|l ohne Programm
914 1 _ |y 2011
915 _ _ |0 StatID:(DE-HGF)0010
|a JCR/ISI refereed
920 1 _ |0 I:(DE-Juel1)INM-2-20090406
|g INM
|k INM-2
|l Molekulare Organisation des Gehirns
|x 0
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|g INM
|k INM-3
|l Kognitive Neurowissenschaften
|x 1
970 _ _ |a VDB:(DE-Juel1)124270
980 _ _ |a VDB
980 _ _ |a ConvertedRecord
980 _ _ |a journal
980 _ _ |a I:(DE-Juel1)INM-2-20090406
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)INM-3-20090406

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21